Skip to main content
LNAI
NASDAQ Life Sciences

Stockholders Approve Reverse Stock Split to Address Nasdaq Delisting

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.294
Mkt Cap
$10.773M
52W Low
$0.151
52W High
$5.5
52W Position info
94% above low
Off High info
95% below high
Rel. Volume
Market data snapshot near publication time

LNAI sits 94% above its 52-week low of $0.151.

Summary

Lunai Bioworks stockholders approved a reverse stock split, a crucial step to regain Nasdaq compliance amidst ongoing delisting threats and financial distress.


Key Events · Corporate Governance and Compliance · LNAI

  • Reverse Stock Split Approved

    Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-3 and 1-for-30, with the Board determining the exact ratio.

  • Nasdaq Compliance Effort

    This approval is a direct response to multiple Nasdaq delisting notices, including a recent one for failing to meet the $35 million market value requirement, and aims to help the company regain compliance with the minimum bid price rule.

  • Ongoing Financial Distress

    The company previously issued a "going concern" warning, furloughed employees, and deferred executive salaries, underscoring its severe financial challenges.


Analysis · LNAI · Life Sciences

Lunai Bioworks Inc. stockholders have approved a reverse stock split, a critical measure to address the company's ongoing non-compliance with Nasdaq's minimum bid price requirement. This action follows multiple delisting notices and a "going concern" warning, highlighting the company's severe financial and operational challenges. While necessary to maintain its public listing, a reverse split does not resolve the underlying business issues and is often viewed as a sign of distress. The Board now has discretion to implement a ratio between 1-for-3 and 1-for-30.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LNAI was trading at $0.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.8M. The 52-week trading range was $0.15 to $5.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LNAI - Latest Insights

LNAI
Oct 23, 2026, 2:21 AM EDT
Source: Seeking Alpha
Importance Score:
9
Price at Filing: $0.380
Real-time Price: $0.091 info
Change: -$0.289 (-76%) info
Market Cap: $829.678K info
LNAI
Oct 22, 2026, 9:38 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.3111
Real-time Price: $0.091 info
Change: -$0.2201 (-71%) info
Market Cap: $829.678K info
LNAI
Oct 13, 2026, 4:55 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.04
Real-time Price: $0.091 info
Change: -$0.949 (-91%) info
Market Cap: $829.678K info
LNAI
Oct 09, 2026, 2:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.18
Real-time Price: $0.091 info
Change: -$1.08 (-92%) info
Market Cap: $829.678K info
LNAI
Sep 22, 2026, 9:20 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $2.40
Real-time Price: $0.091 info
Change: -$2.31 (-96%) info
Market Cap: $829.678K info